G 蛋白偶聯受體市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、分析類型、應用、地區和競爭細分，2020-2030 年預測

2024 年全球 G 蛋白偶聯受體市場價值為 39.5 億美元，預計到 2030 年將達到 53.7 億美元，複合年成長率為 5.23%。全球G 蛋白偶聯受體 (GPCR) 市場因其在藥物發現和疾病治療中的關鍵作用而見證顯著成長。 GPCR 是最大的膜蛋白類別之一，是多種治療應用的主要靶點，包括神經系統疾病、心血管疾病和癌症。由於 FDA 批准的所有藥物中近 40% 都針對 GPCR，製藥和生物技術公司正在大力投資 GPCR 研究以開發新型治療方法。高通量篩選技術與低溫電子顯微鏡等結構生物學進步的結合加速了藥物研發過程。該公司正專注於 GPCR 靶向生物製劑、小分子調節劑和變構調節劑，以提高藥物的特異性和功效，推動市場向前發展。

市場概況
預測期	2026-2030
2024 年市場規模	39.5 億美元
2030 年市場規模	53.7 億美元
2025-2030 年複合年成長率	5.23%
成長最快的領域	發炎研究
最大的市場	北美洲

代謝紊亂、神經系統疾病和癌症等慢性疾病的發生率不斷上升，推動了對 GPCR 標靶治療的需求。製藥業正在利用人工智慧 (AI) 和機器學習來最佳化 GPCR 藥物開發，從而發現新的受體標靶並改善藥物設計。生物感測器和非標記檢測技術的進步增強了 GPCR 篩選能力，提高了候選藥物辨識的效率。精準醫療的擴展和對個人化治療日益成長的興趣也推動了 GPCR 調節的研究。針對 GPCR 通路的藥物再利用策略正在為現有分子創造新的機會、降低開發成本並加快監管部門的批准。計算建模和模擬技術的日益普及進一步有助於基於 GPCR 結構的藥物設計，提高臨床試驗的成功率。

儘管取得了令人鼓舞的進展，GPCR 市場仍面臨 GPCR 訊號通路的複雜性和受體表徵困難等挑戰。許多 GPCR 仍然是具有未知內源性配體的孤兒受體，這限制了它們的治療靶向潛力。以 GPCR 為重點的藥物研發成本高昂，包括對先進篩選技術和結構研究的投資，這對小型生物技術公司構成了財務限制。由於 GPCR 參與許多生理過程，確保藥物特異性同時最大限度地減少脫靶效應仍然是一個關鍵問題。新型 GPCR 標靶藥物的監管障礙可能會延遲商業化，需要進行大量的臨床驗證和安全評估。透過受體生物學的不斷創新、新的藥物傳遞方法和策略性產業合作來應對這些挑戰將是釋放 GPCR 標靶治療全部潛力的關鍵。

主要市場促進因素

擴展 GPCR 在神經和精神疾病領域的研究

增加對免疫腫瘤學和 GPCR 標靶癌症療法的投資

生物製劑和胜肽 GPCR 療法的應用日益廣泛

主要市場挑戰

GPCR結構與訊息傳遞路徑的複雜性

GPCR 藥物研發的高流失率

主要市場趨勢

越來越重視偏向激動劑以增強治療效果

人工智慧在 GPCR 藥物研發的應用日益廣泛

分段洞察

產品洞察

檢測類型洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球 G 蛋白偶聯受體市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 副產物（細胞株、檢測試劑盒、細胞培養試劑、配體）
  • 依檢測類型（cAMP 功能檢測、鈣功能檢測、B-Arrestin 功能檢測、放射性配體結合和 GTPYS 功能檢測、內化檢測、運輸檢測、其他）
  • 按應用（癌症研究、中樞神經系統研究、代謝研究、心血管研究、呼吸系統研究、發炎研究、其他）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第 6 章：北美 G 蛋白偶聯受體市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 7 章：歐洲 G 蛋白偶聯受體市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太地區 G 蛋白偶聯受體市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 韓國
  • 日本
  • 澳洲

第 9 章：南美洲 G 蛋白偶聯受體市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲 G 蛋白偶聯受體市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• Promega Corporation
• Merck KGaA
• Abcam plc
• Becton, Dickinson and Company
• Danaher Corporation
• QIAGEN NV
• Bio-Techne Corporation
• WuXi AppTec

第 15 章：策略建議

第16章 關於出版商,免責事項

Global G-Protein Coupled Receptors Market was valued at USD 3.95 Billion in 2024 and is expected to reach USD 5.37 Billion in the forecast period with a CAGR of 5.23% through 2030. The Global G-Protein Coupled Receptors (GPCR) Market is witnessing significant growth due to its critical role in drug discovery and disease treatment. GPCRs represent one of the largest classes of membrane proteins and serve as primary targets for a wide range of therapeutic applications, including neurological disorders, cardiovascular diseases, and cancer. With nearly 40% of all FDA-approved drugs targeting GPCRs, pharmaceutical and biotechnology companies are investing heavily in GPCR research to develop novel therapeutics. The integration of high-throughput screening technologies and advancements in structural biology, such as cryo-electron microscopy, has accelerated drug discovery efforts. Companies are focusing on GPCR-targeted biologics, small molecule modulators, and allosteric modulators to enhance drug specificity and efficacy, driving the market forward.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 3.95 Billion
Market Size 2030	USD 5.37 Billion
CAGR 2025-2030	5.23%
Fastest Growing Segment	Inflammation Research
Largest Market	North America

The rising prevalence of chronic diseases, including metabolic disorders, neurological conditions, and cancer, is driving the demand for GPCR-targeted therapeutics. The pharmaceutical industry is leveraging artificial intelligence (AI) and machine learning to optimize GPCR drug development, leading to the discovery of new receptor targets and improved drug design. Advances in biosensors and label-free detection technologies have enhanced GPCR screening capabilities, improving efficiency in drug candidate identification. The expansion of precision medicine and the growing interest in personalized therapies have also fueled research in GPCR modulation. Drug repurposing strategies targeting GPCR pathways are creating new opportunities for existing molecules, reducing development costs and accelerating regulatory approvals. The increasing adoption of computational modeling and simulation techniques is further aiding in GPCR structure-based drug design, enhancing success rates in clinical trials.

Despite the promising advancements, the GPCR market faces challenges such as the complexity of GPCR signaling pathways and difficulties in receptor characterization. Many GPCRs remain orphan receptors with unknown endogenous ligands, limiting their therapeutic targeting potential. The high costs associated with GPCR-focused drug discovery, including investments in advanced screening technologies and structural studies, pose financial constraints for smaller biotech firms. Ensuring drug specificity while minimizing off-target effects remains a critical concern, as GPCRs are involved in numerous physiological processes. Regulatory hurdles for novel GPCR-targeted drugs can delay commercialization, requiring extensive clinical validation and safety assessments. Addressing these challenges through continuous innovation in receptor biology, novel drug delivery approaches, and strategic industry collaborations will be key to unlocking the full potential of GPCR-targeted therapeutics.

Key Market Drivers

Expansion of GPCR Research in Neurological and Psychiatric Disorders

The expansion of G-Protein Coupled Receptor (GPCR) research in neurological and psychiatric disorders is significantly driving the growth of the Global GPCR Market. GPCRs are integral to neurotransmission, influencing critical neurological functions such as cognition, mood regulation, pain perception, and motor control. Dysregulation of GPCR signaling pathways has been implicated in various disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression, and anxiety. The increasing prevalence of these conditions has intensified efforts to develop GPCR-targeted therapies.

According to the National Institute of Mental Health (NIMH), in 2022, approximately 59.3 million adults in the United States experienced mental illness, representing 23.1% of the adult population. This substantial prevalence underscores the urgent need for effective treatments. Advancements in GPCR structural biology, computational modeling, and high-throughput screening technologies have facilitated the identification of novel GPCR modulators for neurological applications. Drug developers are increasingly focusing on biased agonism and allosteric modulation to enhance the selectivity of GPCR-targeted compounds, aiming to improve therapeutic outcomes while minimizing adverse effects.

Government and private funding for neuroscience research have surged, supporting large-scale initiatives aimed at decoding GPCR functions in the central nervous system. Collaborations between academia, biotech firms, and pharmaceutical companies have strengthened the development pipeline for GPCR-targeted drugs, leading to an increasing number of clinical trials focused on novel neurological treatments. The integration of artificial intelligence and machine learning in GPCR drug discovery has further optimized lead compound identification, accelerating the transition from preclinical research to market-ready therapeutics. As the demand for safer and more effective neurological treatments grows, the expansion of GPCR research in this field is expected to remain a key driver of market growth, fostering innovation and transforming therapeutic strategies for central nervous system disorders.

Increasing Investments in Immuno-Oncology and GPCR-Targeted Cancer Therapies

Increasing investments in immuno-oncology and GPCR-targeted cancer therapies are significantly driving the growth of the Global G-Protein Coupled Receptors (GPCR) Market. GPCRs play a crucial role in cancer biology by regulating tumor progression, metastasis, and immune system modulation. The growing recognition of GPCRs as viable drug targets for oncology has led to an influx of funding from pharmaceutical companies, biotech firms, and research institutions. These investments are fueling the development of novel GPCR-targeted therapies aimed at enhancing immune response against cancer cells, reducing tumor growth, and improving treatment efficacy.

Several immuno-oncology drugs targeting GPCRs are in various stages of clinical development, reflecting the pharmaceutical industry's commitment to leveraging these receptors in cancer therapeutics. Companies are exploring GPCR modulators to enhance immune checkpoint blockade therapies, improving the response rates in patients with treatment-resistant tumors. Advances in GPCR structural biology and computational drug design are accelerating the identification of selective GPCR inhibitors and agonists with higher efficacy and fewer side effects. These developments have led to an increase in clinical trials evaluating GPCR-targeted immunotherapies across different cancer types, including lung, breast, and colorectal cancers.

Strategic collaborations between biotech startups, pharmaceutical giants, and academic institutions are further strengthening the GPCR oncology pipeline. Government funding and venture capital investments are also playing a pivotal role in accelerating research efforts. The introduction of advanced screening technologies and artificial intelligence-driven drug discovery platforms has improved the efficiency of identifying potential GPCR-based cancer drugs. As the demand for targeted cancer therapies grows, the increasing investments in immuno-oncology and GPCR-based treatments are expected to expand the therapeutic landscape, making GPCRs a central focus in the development of next-generation cancer drugs.

Rising Adoption of Biologics and Peptide-Based GPCR Therapies

The rising adoption of biologics and peptide-based therapies targeting G-Protein Coupled Receptors (GPCRs) is driving the growth of the Global GPCR Market. GPCRs represent one of the most diverse and crucial receptor families involved in various physiological processes, making them attractive drug targets for treating chronic diseases such as cancer, metabolic disorders, and autoimmune conditions. While small-molecule drugs have traditionally dominated GPCR-targeted therapies, the increasing focus on biologics and peptides has opened new avenues for precision medicine. Peptide-based drugs offer higher specificity, lower toxicity, and improved safety profiles, making them a preferred choice for targeting complex GPCR signaling pathways.

The pharmaceutical industry has significantly invested in peptide and biologic GPCR therapeutics due to their enhanced efficacy and ability to modulate previously undruggable targets. Advances in peptide engineering, including cyclic peptides and stapled peptides, have improved stability and bioavailability, further boosting their adoption. Monoclonal antibodies (mAbs) targeting GPCRs have also gained traction, offering long-lasting therapeutic effects and greater selectivity compared to traditional small molecules. The approval of biologic GPCR-targeted drugs such as erenumab for migraine and mogamulizumab for T-cell lymphoma has demonstrated the clinical success of these therapies, encouraging further innovation.

The expansion of biopharmaceutical research, coupled with increasing regulatory approvals for peptide-based GPCR drugs, has strengthened market growth. Pharmaceutical companies are focusing on developing novel formulations and delivery mechanisms to enhance the therapeutic potential of biologics and peptides. Strategic collaborations between biotech firms and academic institutions have accelerated GPCR drug discovery, leading to the introduction of next-generation therapeutics. With the growing demand for safer and more effective treatments, the shift toward biologics and peptide-based therapies continues to reshape the GPCR market, driving innovation and expanding treatment options for a wide range of diseases.

Key Market Challenges

Complexity of GPCR Structure and Signaling Pathways

The complexity of GPCR structure and signaling pathways presents a significant challenge for the Global G-Protein Coupled Receptors (GPCR) Market. GPCRs are one of the largest families of cell surface receptors, and they mediate a wide variety of physiological processes, including neurotransmission, immune response, and hormonal regulation. Their intricate structure, characterized by seven transmembrane domains and the involvement of multiple intracellular signaling pathways, makes understanding and targeting these receptors difficult. Each GPCR can couple with various G-protein subtypes, leading to a diverse range of cellular responses. This variability poses challenges in developing precise, selective therapeutics that can modulate specific signaling pathways without causing off-target effects.

The diverse and sometimes contradictory signaling pathways activated by GPCRs require sophisticated methods for their study and characterization. Identifying specific ligand-receptor interactions and understanding how different receptors contribute to disease pathology can be time-consuming and resource-intensive. This complexity is compounded by the dynamic nature of GPCRs, which can undergo conformational changes upon ligand binding, further complicating their study. Additionally, the lack of high-resolution structural data for many GPCRs hinders the design of drugs that specifically target these receptors with minimal side effects.

As a result, researchers face significant challenges in developing effective GPCR-based therapeutics. The high costs and long timelines associated with studying the structure and function of these receptors can slow the pace of innovation. Addressing these challenges requires advancements in structural biology, computational modeling, and drug screening technologies, all of which are essential to unlock the full potential of GPCRs in drug development.

High Attrition Rates in GPCR Drug Development

High attrition rates in GPCR drug development present a significant challenge in the Global G-Protein Coupled Receptors (GPCR) Market. The drug discovery process for GPCRs is notoriously complex, and despite their vast therapeutic potential, many GPCR-targeted compounds fail during clinical trials. This high failure rate is attributed to several factors, including the difficulty in designing selective and effective drug candidates that target specific GPCR subtypes without causing off-target effects. The structural complexity of GPCRs and their involvement in diverse signaling pathways make it challenging to predict the pharmacological responses of potential drugs accurately.

The lack of reliable biomarkers to predict therapeutic outcomes is another barrier that contributes to the high attrition rates. Without these biomarkers, it becomes challenging to monitor a drug's efficacy early in the development process, often resulting in late-stage failures when the drugs are no longer viable for commercialization. Additionally, adverse safety profiles, such as unintended side effects or toxicity, frequently emerge during clinical testing, leading to the discontinuation of several promising drug candidates.

The resource-intensive nature of GPCR drug development further compounds the issue. The lengthy and expensive process, from discovery through to clinical trials, often results in substantial financial losses for companies when a drug fails to meet the required endpoints. These high attrition rates can deter investment in GPCR drug development, slowing down the progress of novel therapeutics. Overcoming these challenges requires the integration of better drug design techniques, more advanced screening technologies, and more comprehensive preclinical testing to identify promising candidates and reduce the risks of failure.

Key Market Trends

Growing Focus on Biased Agonism for Enhanced Therapeutic Efficacy

The growing focus on biased agonism is becoming a key trend in the Global G-Protein Coupled Receptors (GPCR) Market due to its potential to enhance therapeutic efficacy and minimize side effects. Biased agonism refers to the ability of a ligand to selectively activate certain signaling pathways downstream of a GPCR, rather than triggering all possible pathways associated with that receptor. This concept has opened new avenues for drug discovery, particularly in the development of more targeted and effective therapies. By focusing on biased signaling, researchers aim to fine-tune GPCR activation to achieve the desired therapeutic effects while avoiding undesirable side effects typically associated with non-selective receptor activation.

The increased understanding of GPCR signaling has highlighted that the same receptor can produce a variety of cellular responses depending on the pathway it activates. This has led to a paradigm shift in drug development, where instead of developing agonists that activate all pathways, drugs are being designed to selectively engage specific pathways, thus improving the precision of treatments. This approach holds significant promise for conditions where conventional GPCR activation has led to limited efficacy or unwanted side effects, such as in neurological disorders, cardiovascular diseases, and pain management.

Pharmaceutical companies are investing heavily in biased agonism strategies as a way to optimize the efficacy of existing drugs and develop novel therapeutic agents. By leveraging advanced screening techniques and novel assay systems, researchers are able to identify compounds that selectively activate specific signaling pathways, potentially leading to the development of safer, more effective treatments. The growing emphasis on biased agonism is poised to shape the future of GPCR-based therapeutics, offering more personalized treatment options for patients across various therapeutic areas.

Recent studies have shown that approximately 320 agents are currently in clinical trials targeting GPCRs, with about 36% focusing on potentially novel GPCR targets without an approved drug. This indicates a significant shift towards exploring new GPCR targets and developing biased agonists, highlighting the growing interest and investment in this area of drug discovery.

Increasing Adoption of Artificial Intelligence in GPCR Drug Discovery

The increasing adoption of artificial intelligence (AI) in G-Protein Coupled Receptors (GPCR) drug discovery is a significant trend driving growth in the Global GPCR Market. AI technologies, particularly machine learning and deep learning, are transforming the way drug discovery is conducted by enhancing the speed, accuracy, and efficiency of identifying potential drug candidates. In GPCR research, AI is being used to predict GPCR-ligand interactions, model receptor structures, and analyze large datasets from high-throughput screening assays. By processing vast amounts of biological, chemical, and molecular data, AI can help researchers identify promising compounds for GPCR targets much faster than traditional methods.

AI-powered algorithms are also aiding in the design of novel GPCR-targeted therapies by predicting how certain compounds will interact with specific receptor subtypes. This can help to develop more selective and effective drugs, reducing the likelihood of side effects and improving therapeutic outcomes. AI tools are particularly beneficial in addressing the challenges of drug design, such as optimizing molecular properties, enhancing drug stability, and ensuring specificity for the desired GPCR targets.

The integration of AI into GPCR drug discovery has also led to cost reduction in the early stages of drug development. This trend is accelerating the progress of research and shortening development timelines, allowing for faster market entry of new GPCR-targeted drugs. With its potential to streamline the drug discovery process and improve the accuracy of predictions, AI is poised to play a key role in the future of GPCR-based therapeutics, making it a dominant trend in the market.

Recent studies have highlighted the significant impact of AI in drug discovery. A review published in the British Journal of Pharmacology discusses how AI approaches are being applied at multiple stages during the drug discovery process, from aiding the understanding of GPCRs to the discovery of new ligand-GPCR interactions and the prediction of clinical responses. The authors anticipate that the application of AI will make the drug discovery process "faster, smarter, and cheaper," creating exciting new opportunities for GPCR drug discovery.

Furthermore, a bibliometric study published in Frontiers in Pharmacology analyzed the application of AI in drug discovery and development, highlighting its role in improving pharmaceutical productivity and accelerating the drug development process. The study notes that AI has revolutionized many aspects of the pharmaceutical industry, including drug discovery and development, drug repurposing, and clinical trials, thereby reducing human workload and achieving targets in a shorter period. These findings underscore the transformative role of AI in enhancing the efficiency and effectiveness of GPCR drug discovery, leading to more rapid development of novel therapeutics.

Segmental Insights

Product Insights

Based on the Product, Detection Kits emerged as the dominant segment in the Global G-Protein Coupled Receptors Market in 2024. This is due to their critical role in drug discovery, signal transduction studies, and high-throughput screening applications. GPCRs are one of the most extensively studied drug targets, and their complex signaling mechanisms require precise and efficient detection methods. Detection kits provide standardized, reliable, and easy-to-use solutions for analyzing GPCR activity, making them indispensable for pharmaceutical and academic research laboratories. The growing demand for GPCR-targeted therapeutics, particularly in oncology, neurology, and inflammation research, has significantly increased the adoption of these kits for screening and validation purposes. The expansion of high-throughput screening (HTS) platforms and advancements in biosensor technologies have further propelled the demand for GPCR detection kits. These kits allow for real-time monitoring of GPCR interactions, aiding in the identification of novel drug candidates with high specificity and efficacy. Additionally, the increasing availability of fluorescence-based and luminescence-based detection assays has enhanced the sensitivity and accuracy of GPCR studies. The convenience, reproducibility, and adaptability of detection kits in both basic and translational research have solidified their position as the leading product segment in the GPCR market.

Assay Type Insights

Based on the Assay Type, cAMP Functional Assays emerged as the dominant segment in the Global G-Protein Coupled Receptors Market in 2024. This dominance is due to their critical role in studying GPCR-mediated signal transduction. GPCRs regulate numerous physiological processes by activating intracellular signaling cascades, with cyclic adenosine monophosphate (cAMP) being one of the most widely used second messengers. Since many GPCRs signal through G-protein subtypes that modulate cAMP levels, these assays provide a highly effective method for evaluating receptor activity, ligand potency, and drug efficacy. The development of fluorescence and luminescence-based cAMP assays has significantly enhanced sensitivity, reproducibility, and real-time monitoring of GPCR activity. Additionally, advancements in biosensor technology and live-cell imaging have further improved the precision of these assays, making them indispensable in drug discovery and pharmacological research. The growing focus on GPCR-targeted therapies, along with the increasing demand for reliable and cost-effective functional assays, has solidified the dominance of cAMP functional assays in the market. Their ability to provide rapid and accurate insights into GPCR activity has made them the preferred choice for researchers worldwide.Regional Insights

North America emerged as the dominant region in the Global G-Protein Coupled Receptors Market in 2024. This is due to the strong presence of pharmaceutical and biotechnology companies, advanced research infrastructure, and significant investment in drug discovery. The region hosts major players actively engaged in GPCR-targeted drug development, leveraging high-throughput screening technologies and innovative assay systems. The increasing prevalence of chronic diseases such as cancer, neurological disorders, and metabolic conditions has driven the demand for GPCR-based therapeutics, leading to greater adoption of detection kits, functional assays, and biosensor technologies. The United States has played a pivotal role in the market's dominance, with its well-established regulatory framework, substantial funding from organizations such as the National Institutes of Health (NIH), and strong collaborations between academic institutions and private enterprises. Additionally, the presence of cutting-edge research facilities and access to state-of-the-art technologies has facilitated advancements in GPCR-targeted drug discovery. The rising focus on personalized medicine and precision therapeutics has further fueled research efforts, leading to the expansion of GPCR studies in North America. With continuous innovation, strong industry-academic partnerships, and increasing R&D expenditure, the region has solidified its position as the leading market for GPCR research and therapeutics.

Key Market Players

• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• Promega Corporation
• Merck KGaA
• Abcam plc
• Becton, Dickinson and Company
• Danaher Corporation
• QIAGEN N.V.
• Bio-Techne Corporation
• WuXi AppTec

Report Scope:

In this report, the Global G-Protein Coupled Receptors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

G-Protein Coupled Receptors Market, By Product:

• Cell Lines
• Detection Kits
• Cell Culture Reagents
• Ligands

G-Protein Coupled Receptors Market, By Assay Type:

• cAMP Functional Assays
• Calcium Functional Assays
• B-Arrestin Functional Assays
• Radioligand Binding & GTPYS Functional Assays
• Internalization Assays
• Trafficking Assays
• Others

G-Protein Coupled Receptors Market, By Application:

• Cancer Research
• CNS Research
• Metabolic Research
• Cardiovascular Research
• Respiratory Research
• Inflammation Research
• Others

G-Protein Coupled Receptors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global G-Protein Coupled Receptors Market.

Available Customizations:

Global G-Protein Coupled Receptors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global G-Protein Coupled Receptors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Cell Lines, Detection Kits, Cell Culture Reagents, Ligands)
  • 5.2.2. By Assay Type (cAMP Functional Assays, Calcium Functional Assays, B-Arrestin Functional Assays, Radioligand Binding & GTPYS Functional Assays, Internalization Assays, Trafficking Assays, Others)
  • 5.2.3. By Application (Cancer Research, CNS Research, Metabolic Research, Cardiovascular Research, Respiratory Research, Inflammation Research, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America G-Protein Coupled Receptors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Assay Type
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States G-Protein Coupled Receptors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Assay Type
      • 6.3.1.2.3. By Application
  • 6.3.2. Mexico G-Protein Coupled Receptors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Assay Type
      • 6.3.2.2.3. By Application
  • 6.3.3. Canada G-Protein Coupled Receptors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Assay Type
      • 6.3.3.2.3. By Application

7. Europe G-Protein Coupled Receptors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Assay Type
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France G-Protein Coupled Receptors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Assay Type
      • 7.3.1.2.3. By Application
  • 7.3.2. Germany G-Protein Coupled Receptors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Assay Type
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom G-Protein Coupled Receptors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Assay Type
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy G-Protein Coupled Receptors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Assay Type
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain G-Protein Coupled Receptors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Assay Type
      • 7.3.5.2.3. By Application

8. Asia-Pacific G-Protein Coupled Receptors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Assay Type
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China G-Protein Coupled Receptors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Assay Type
      • 8.3.1.2.3. By Application
  • 8.3.2. India G-Protein Coupled Receptors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Assay Type
      • 8.3.2.2.3. By Application
  • 8.3.3. South Korea G-Protein Coupled Receptors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Assay Type
      • 8.3.3.2.3. By Application
  • 8.3.4. Japan G-Protein Coupled Receptors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Assay Type
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia G-Protein Coupled Receptors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Assay Type
      • 8.3.5.2.3. By Application

9. South America G-Protein Coupled Receptors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Assay Type
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil G-Protein Coupled Receptors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Assay Type
      • 9.3.1.2.3. By Application
  • 9.3.2. Argentina G-Protein Coupled Receptors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Assay Type
      • 9.3.2.2.3. By Application
  • 9.3.3. Colombia G-Protein Coupled Receptors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Assay Type
      • 9.3.3.2.3. By Application

10. Middle East and Africa G-Protein Coupled Receptors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Assay Type
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa G-Protein Coupled Receptors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Assay Type
      • 10.3.1.2.3. By Application
  • 10.3.2. Saudi Arabia G-Protein Coupled Receptors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Assay Type
      • 10.3.2.2.3. By Application
  • 10.3.3. UAE G-Protein Coupled Receptors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Assay Type
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. PerkinElmer Inc.
• 14.3. Promega Corporation
• 14.4. Merck KGaA
• 14.5. Abcam plc
• 14.6. Becton, Dickinson and Company
• 14.7. Danaher Corporation
• 14.8. QIAGEN N.V.
• 14.9. Bio-Techne Corporation
• 14.10. WuXi AppTec

15. Strategic Recommendations

16. About Us & Disclaimer